Study guide
3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs
Key Takeaways Explain This Topic AI
Cardiogenic shock is defined hemodynamically by persistent tissue hypoperfusion resulting from primary cardiac pump failure, characterized by a cardiac index <2.2 L/min/m², elevated pulmonary capillary wedge pressure >15 mmHg, and compensatory elevated systemic vascular resistance >1200 dynes·sec/cm⁵.
Norepinephrine is the first-line vasopressor of choice in cardiogenic shock complicated by hypotension; in SOAP II dopamine nearly doubled arrhythmias overall and was associated with higher 28-day mortality in the cardiogenic shock subgroup.
Dobutamine (2.5–20 mcg/kg/min) acts predominantly on β1 > β2 receptors to increase cardiac contractility with mild vasodilation, whereas milrinone (0.125–0.75 mcg/kg/min) is a PDE-3 inhibitor that produces inodilation with afterload reduction but has a prolonged half-life requiring substantial dose adjustments in renal impairment.
Mechanical circulatory support (MCS) modalities in the ED—including IABP, Impella microaxial pumps, and VA-ECMO—provide emergency bridge-to-decision support and require mandatory systemic anticoagulation (typically unfractionated heparin targeting anti-Xa 0.3–0.7 IU/mL).
Obstructive shock results from extracardiac flow restriction; massive pulmonary embolism with hemodynamic instability mandates immediate systemic thrombolysis (e.g., Alteplase 100 mg IV over 2 hours), while cardiac tamponade necessitates urgent pericardiocentesis and strict avoidance of vasodilators and diuresis.
Last updated: October 2026
- Cardiogenic & Obstructive Shock Hemodynamics
- Cardiogenic Shock Pathophysiology and Hemodynamic Profiles
Cardiogenic shock is a state of critical end-organ hypoperfusion caused by primary cardiac pump failure. Hemodynamically, it is defined by:
Depressed Cardiac Index (CI) : <2.2 L/min/m² (or <1.8 L/min/m² without pharmacologic or mechanical support).
Elevated Ventricular Filling Pressures : Pulmonary capillary wedge pressure (PCWP) >15–18 mmHg and central venous pressure (CVP) >10–12 mmHg.
Elevated Systemic Vascular Resistance (SVR) : Typically >1200 dynes·sec/cm⁵, reflecting compensatory neurohormonal vasoconstriction mediated by the sympathetic nervous system and renin-angiotensin-aldosterone axis.
Tissue Hypoperfusion : Sustained systolic blood pressure (SBP) <90 mmHg or MAP <65 mmHg, accompanied by cool extremities, oliguria (<0.5 mL/kg/hr), altered mentation, and elevated serum lactate.
- Shock Classification Cardiac Index (CI) Preload (CVP / PCWP) Afterload (SVR) Mixed Venous Oxygen (SvO₂)
- Cardiogenic Markedly Low (<2.2) Elevated (>15 mmHg) Elevated (>1200) Low (<65%)
- Distributive (Septic) High (early) / Normal Normal to Low Markedly Low (<800) High (>70%)
- Hypovolemic Low Markedly Low (<5 mmHg) Elevated (>1200) Low (<65%)
- Obstructive Low Variable (CVP ↑, PCWP ↓ or ↑) Elevated (>1200) Low (<65%)
- Primary Etiologies
Acute Myocardial Infarction (AMI) : The most frequent cause (~80% of cases), typically involving extensive left ventricular anterior wall infarction (>40% myocardium loss) or isolated right ventricular (RV) infarction.
Acute Decompensated Heart Failure (ADHF) : End-stage ischemic or non-ischemic cardiomyopathy with chronic low-output decompensation.
Mechanical Complications of AMI : Acute mitral regurgitation from papillary muscle rupture, acute ventricular septal rupture (VSR), or free wall rupture.
Acute Fulminant Myocarditis & Toxic Ingestion : Severe lymphocytic/giant-cell myocarditis or cardiotoxic overdose (e.g., beta-blockers, calcium channel blockers).
Inotrope Selection: Dobutamine vs. Milrinone
Inotropic agents increase myocardial contractility to enhance stroke volume and cardiac output. The choice between adrenergic agonists and phosphodiesterase inhibitors depends on baseline blood pressure, heart rate, renal clearance, and concomitant chronic beta-blocker therapy.
Parameter Dobutamine Milrinone Epinephrine (Low-to-Mid Dose)
Mechanism of Action Synthetic catecholamine; direct β₁ agonist (+++), moderate β₂ (++), weak α₁ (+) Phosphodiesterase-3 (PDE-3) inhibitor; prevents intracellular cAMP degradation Endogenous catecholamine; potent β₁ (+++), moderate β₂ (++), α₁ (+++)
Hemodynamic Effects ↑ Contractility (inotropy); ↑ Heart rate (chronotropy); Mild ↓ SVR (vasodilation) ↑ Inotropy; Modest ↑ Chronotropy; Potent ↓ SVR & ↓ PVR (inodilator) ↑↑ Inotropy; ↑↑ Chronotropy; ↑ SVR (at doses >0.05 mcg/kg/min)
Onset / Elimination t½ Onset 1–2 min; t½ ~2 minutes Onset 5–15 min; t½ 2.5 hours (prolonged to 4–10+ hours in renal failure) Onset 1–2 min; t½ ~2 minutes
Elimination Route Hepatic methylation (COMT) Renal excretion (80–90% unchanged) Hepatic and tissue clearance
Usual Infusion Dose 2.5–20 mcg/kg/min continuous IV 0.125–0.75 mcg/kg/min continuous IV 0.01–0.1 mcg/kg/min (inotropic range)
ED Loading Dose None AVOID / OMIT in acute settings None
Key Adverse Effects Tachyarrhythmias, angina, myocardial ischemia, tachyphylaxis (>72h) Severe refractory hypotension, ventricular arrhythmias, thrombocytopenia Severe tachycardia, tachyarrhythmias, elevated serum lactate, ischemia
Clinical Distinctions and Pitfalls
Dobutamine in Acute Hypotension : Dobutamine stimulates vascular β₂ receptors, which can cause peripheral vasodilation. If initiated in a patient with profound hypotension (SBP <85 mmHg), dobutamine can worsen arterial hypotension. In such cases, norepinephrine must be initiated first to restore an adequate perfusion pressure (MAP ≥65 mmHg) before initiating dobutamine.
Milrinone and Renal Impairment : Because milrinone is cleared 80% to 90% unchanged by the kidneys, patients with acute kidney injury or chronic renal failure (creatinine clearance <30 mL/min) will experience significant drug accumulation. The elimination half-life can prolong up to 10 hours. In the emergency department, the manufacturer-described IV loading dose (50 mcg/kg) must be omitted to prevent sudden severe hypotension and vascular collapse.
Chronic Beta-Blocker Therapy : Patients maintained on chronic beta-blockers (e.g., carvedilol, metoprolol succinate) have competitively blocked β₁ receptors. Dobutamine is often ineffective or requires excessive doses in this population. Milrinone acts downstream of the beta-adrenergic receptor by inhibiting PDE-3, bypassing receptor blockade and making it the preferred inotrope in chronic beta-blocker therapy.
Vasopressor Support in Cardiogenic Shock: Norepinephrine vs. Dopamine
When cardiogenic shock presents with severe hypotension (SBP <90 mmHg, MAP <65 mmHg), vasopressor therapy is mandatory to preserve coronary and cerebral perfusion pressure while inotropes are introduced.
The SOAP II Trial Evidence
For decades, dopamine was widely used as the initial vasopressor for cardiogenic shock. The landmark SOAP II trial (Sepsis Occurrence in Acutely Ill Patients II, NEJM 2010) randomized 1,679 patients with shock to either dopamine or norepinephrine. In the predefined subgroup analysis of 280 patients with cardiogenic shock:
In the predefined cardiogenic shock subgroup (280 patients) , dopamine was associated with higher 28-day mortality than norepinephrine (P = 0.03 on Kaplan-Meier analysis). Overall trial mortality did not differ significantly.
Across all 1,679 patients, arrhythmic events were nearly twice as common with dopamine (24.1% vs. 12.4%, p < 0.001), mostly atrial fibrillation, and more dopamine patients stopped the study drug because of severe arrhythmias.
Dopamine exerts substantial β₁-adrenergic chronotropic stimulation, increasing myocardial oxygen consumption (MVO₂) in an already ischemic and failing ventricle.
Important
Norepinephrine is the first-line vasopressor of choice in cardiogenic shock . Dopamine is strongly discouraged and should not be used as first-line therapy.
Mechanical Circulatory Support (MCS) in the Emergency Department
When pharmacologic inotropic and vasopressor therapy fails to restore adequate cardiac output, temporary mechanical circulatory support (MCS) serves as an emergency bridge to percutaneous coronary intervention (PCI), surgical revascularization, durable ventricular assist device (VAD), or recovery.
Device Mechanism & Cannulation Hemodynamic Impact Anticoagulation Mandate
Intra-Aortic Balloon Pump (IABP) Counterpulsation balloon placed in descending thoracic aorta via femoral artery; inflates during diastole, deflates during systole. ↑ Diastolic coronary perfusion, ↓ LV afterload, modest ↑ CO (0.5 L/min), ↓ myocardial oxygen demand (MVO₂). Therapeutic Unfractionated Heparin (UFH) continuous infusion; monitor aPTT or anti-Xa.
Impella (e.g., CP, 5.0) Catheter-mounted microaxial Archimedes-screw pump inserted retrograde across aortic valve into left ventricle. Directly unloads left ventricle, draws blood from LV into ascending aorta; provides 3.5 to 5.0 L/min active forward flow. Purge solution contains heparin (e.g., D5W with 25 or 50 units/mL heparin) plus systemic IV heparin targeting anti-Xa 0.3–0.7 IU/mL.
Venoarterial ECMO (VA-ECMO) Cannulation drains deoxygenated venous blood from right atrium/femoral vein, passes through membrane oxygenator, and returns under pressure to femoral artery. Full biventricular hemodynamic support (up to 5–7 L/min) and complete respiratory gas exchange; increases LV afterload . Systemic IV UFH targeting anti-Xa 0.3–0.7 IU/mL or aPTT 60–80 seconds; direct thrombin inhibitor (Bivalirudin) if HIT suspected.
Warning
VA-ECMO pumps blood retrogradely up the descending aorta against the native left ventricular ejection. This substantially increases left ventricular afterload. If the failing LV cannot overcome this pressure, left ventricular distension, intra-cardiac stasis, pulmonary edema, and intracardiac thrombus can occur. Emergency venting with an Impella (termed "ECPELLA") or atrial septostomy is frequently required.
Durable LVADs, Mechanical CPR and ECPR
Patients with a durable left ventricular assist device (LVAD) , now mostly the continuous-flow HeartMate 3, increasingly present to the ED.
Assessment : continuous flow may leave no palpable pulse and an unreliable pulse oximeter. Measure blood pressure by Doppler ; the opening pressure approximates the MAP, which programs commonly target around 70 to 90 mmHg. Check the controller for alarms, power and flow.
Anticoagulation : the HeartMate 3 regimen is warfarin to an INR of 2 to 3 . The ARIES-HM3 trial (2023) showed that dropping aspirin reduced bleeding without more thromboembolism, so many programs now use warfarin alone.
Bleeding : GI bleeding from arteriovenous malformations and acquired von Willebrand deficiency is the most common complication. Reverse warfarin cautiously and only to the degree the bleed requires, in discussion with the LVAD team, because aggressive reversal (high-dose 4F-PCC or vitamin K) raises the risk of pump thrombosis.
Pump thrombosis : suspect it with hemolysis (rising LDH, dark urine) and power spikes. Treatment escalates anticoagulation with heparin; fibrinolysis or pump exchange is decided by the LVAD center.
Arrest : if the pump has stopped and the patient is unresponsive with a MAP below 50 mmHg or end-tidal CO2 below 20 mmHg, chest compressions are appropriate (AHA scientific statement on LVAD resuscitation). Treat hypertension above the target MAP promptly, because it raises the stroke risk.
Mechanical CPR devices (LUCAS, AutoPulse) are not better than good manual CPR. They are reasonable when high-quality manual compressions are impractical, such as during transport, prolonged resuscitation, in the catheterization laboratory, or as a bridge to extracorporeal CPR (ECPR) . For selected patients with refractory arrest in experienced systems, ECPR with VA-ECMO can bridge to reperfusion. Drug doses do not change with a mechanical device.
Note
ECMO circuits sequester lipophilic, highly protein-bound drugs (fentanyl, midazolam, propofol, voriconazole) and the priming volume enlarges the volume of distribution. Expect higher sedative and analgesic requirements and use therapeutic drug monitoring where available.
Obstructive Shock Hemodynamics and Pharmacotherapy
Obstructive shock occurs when physical extracardiac barriers impede venous return to the heart (impaired diastolic filling) or obstruct cardiac ejection into the pulmonary or systemic circulation.
1. Massive Pulmonary Embolism (PE)
Massive (high-risk) PE is characterized by acute pulmonary vascular occlusion resulting in acute right ventricular failure and hemodynamic collapse (sustained SBP <90 mmHg for >15 minutes, vasopressor requirement, or cardiac arrest).
Systemic Thrombolytic Pharmacotherapy :
Alteplase (tPA) : 100 mg IV infusion over 2 hours .
In cardiac arrest or impending periarrest collapse: 50 mg IV bolus over 2 minutes , with a second 50 mg IV bolus 15 minutes later if return of spontaneous circulation (ROSC) is not achieved.
Off-label alternative: Tenecteplase (TNK) single weight-based IV bolus (30–50 mg).
Anticoagulation Coordination : Therapeutic unfractionated heparin (UFH) is the preferred anticoagulant in massive PE due to its short half-life and reversibility with protamine. When administering systemic alteplase, the UFH infusion is typically paused or initiated without an initial loading bolus once the aPTT falls below twice normal control.
2. Cardiac Tamponade
Pericardial fluid accumulates under pressure, compressing all four cardiac chambers, equalizing intracardiac diastolic pressures, and severely restricting ventricular filling.
Clinical Presentation : Beck's triad (hypotension, jugular venous distension, muffled heart sounds) and pulsus paradoxus (an inspiratory systolic blood pressure drop >10 mmHg).
Emergency Intervention : Immediate emergency bedside pericardiocentesis or subxiphoid surgical pericardial window.
Pharmacotherapy Principles :
Administer judicious intravenous crystalloid boluses (500–1,000 mL) to elevate intravascular filling pressures and temporize cardiac filling while pericardiocentesis is prepared.
Strictly avoid : Vasodilators, beta-blockers, and aggressive diuresis (which eliminate necessary preload and precipitate total hemodynamic arrest). Avoid positive-pressure mechanical ventilation if possible, as increased intrathoracic pressure halts right-heart venous return.
3. Tension Pneumothorax
Positive intrapleural pressure collapses the ipsilateral lung, shifts the mediastinum to the contralateral side, kinks the superior and inferior vena cava, and arrests venous return.
Emergency Action : Immediate needle thoracostomy (utilizing an 8 cm 14-gauge catheter placed in the 2nd intercostal space at the midclavicular line or 4th/5th intercostal space at the anterior axillary line) followed immediately by tube thoracostomy (chest tube). Do not await radiographic confirmation.